These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 21905064)

  • 41. [5-alpha reductase inhibitors or alpha blockers? The combination brakes best prostatic hyperplasia].
    MMW Fortschr Med; 2002 Oct; 144(44):56. PubMed ID: 12494605
    [No Abstract]   [Full Text] [Related]  

  • 42. Test homogeneity of odds ratio in a randomized clinical trial with noncompliance.
    Lui KJ; Chang KC
    J Biopharm Stat; 2009 Sep; 19(5):916-32. PubMed ID: 20183452
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Varying cluster sizes in trials with clusters in one treatment arm: sample size adjustments when testing treatment effects with linear mixed models.
    Candel MJ; Van Breukelen GJ
    Stat Med; 2009 Aug; 28(18):2307-24. PubMed ID: 19472169
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dutasteride: a dual 5-alpha reductase inhibitor for the treatment of symptomatic benign prostatic hyperplasia.
    Dolder CR
    Ann Pharmacother; 2006 Apr; 40(4):658-65. PubMed ID: 16569804
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [The effect of 5-alpha-reductase inhibitors on benign prostatic hyperplasia].
    Djavan B; McConnell J
    Wien Med Wochenschr; 1996; 146(8):165-8. PubMed ID: 8767401
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A hybrid approach to achieving both marginal and conditional balances for stratification variables in sequential clinical trials.
    Lin Y; Su Z
    Pharm Stat; 2013; 12(5):275-81. PubMed ID: 23897862
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A general framework of marker design with optimal allocation to assess clinical utility.
    Tang L; Zhou XH
    Stat Med; 2013 Feb; 32(4):620-30. PubMed ID: 22833434
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Multi-centre trial analysis revisited.
    Gould AL
    Stat Med; 1998 Aug 15-30; 17(15-16):1779-97; discussion 1799-800. PubMed ID: 9749447
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Testing each hypothesis marginally at alpha while still controlling FWER: how and when.
    Li JD
    Stat Med; 2013 May; 32(10):1730-8. PubMed ID: 22806832
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Optimal allocation of sample sizes to multicenter clinical trials.
    Lai D; Chang KC; Rahbar MH; Moye LA
    J Biopharm Stat; 2013; 23(4):818-28. PubMed ID: 23786227
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bayesian analysis of multicentre trial outcomes.
    Gould AL
    Stat Methods Med Res; 2005 Jun; 14(3):249-80. PubMed ID: 15969303
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Analysis of multicentre trials with continuous outcomes: when and how should we account for centre effects?
    Kahan BC; Morris TP
    Stat Med; 2013 Mar; 32(7):1136-49. PubMed ID: 23112128
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Assessing the consistency of the treatment effect under the discrete random effects model in multiregional clinical trials.
    Liu JT; Tsou HH; Gordon Lan KK; Chen CT; Lai YH; Chang WJ; Tzeng CS; Hsiao CF
    Stat Med; 2016 Jun; 35(14):2301-14. PubMed ID: 26833851
    [TBL] [Abstract][Full Text] [Related]  

  • 54. On Stratified Adjusted Tests by Binomial Trials.
    Shimokawa A; Miyaoka E
    Int J Biostat; 2017 Feb; 13(1):. PubMed ID: 28195544
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Power and sample size calculation incorporating misspecifications of the variance function in comparative clinical trials with over-dispersed count data.
    Igeta M; Takahashi K; Matsui S
    Biometrics; 2018 Dec; 74(4):1459-1467. PubMed ID: 29579337
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Testing homogeneity of stratum effects in stratified paired binary data.
    Zhao YD; Rahardja D; Wang DH; Shen H
    J Biopharm Stat; 2014; 24(3):600-7. PubMed ID: 24697196
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Analysing repeated measurements data: a practical comparison of methods.
    Omar RZ; Wright EM; Turner RM; Thompson SG
    Stat Med; 1999 Jul; 18(13):1587-603. PubMed ID: 10407231
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adjusting for misclassification in a stratified biomarker clinical trial.
    Liu C; Liu A; Hu J; Yuan V; Halabi S
    Stat Med; 2014 Aug; 33(18):3100-13. PubMed ID: 24733510
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Components of variance in a group-randomized trial analysed via a random-coefficients model: the Rapid Early Action for Coronary Treatment (REACT) trial.
    Murray DM; Feldman HA; McGovern PG
    Stat Methods Med Res; 2000 Apr; 9(2):117-33. PubMed ID: 10946430
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A SAS macro for sample size re-estimation.
    Zellner D; Zellner GE; Keller F
    Comput Methods Programs Biomed; 2001 Jun; 65(3):183-90. PubMed ID: 11339980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.